Evaluating integrative care for patients undergoing surgery for thoracic cancers
Official title: Pioneering Pre- and Post-Operative Integrative Care to Improve Thoracic Cancer Quality of Care - The Thoracic Peri-Operative Integrative Surgical Care Evaluation (POISE) Trial - Stage III
Run by Ottawa Hospital Research Institute · NCT04871412 · Data updated 2026-11-12
This study is testing whether adding natural health products like Vitamin D3, probiotics, and whey protein can help improve recovery and quality of life for patients having surgery for lung, gastric, and esophageal cancers.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | Ottawa Hospital Research Institute Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 2 sites (Ottawa, Ontario and 1 other locations) |
| Status | Recruiting |
| Started | April 4, 2022 |
| Main results expected | December 1, 2028 |
| Study ends | December 1, 2029 |
| Registry record updated | January 30, 2026 |
| Trial ID | NCT04871412 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults eligible for complete resection of lung, gastric, or esophageal cancer.
✕Probably not a fit
Patients with small cell or carcinoid tumors, those currently receiving treatment for cancer, or pregnant/breastfeeding women may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial aims to improve outcomes for patients undergoing curative surgery for lung, gastric, and esophageal cancers by integrating complementary health products into their care. The study will assess the impact of various natural health products, including Vitamin D3, probiotics, and whey protein, on patient recovery and quality of life. By focusing on a multi-faceted approach rather than single-agent therapies, the trial seeks to address the high rates of adverse events and concerns about cancer recurrence. The overarching goal is to enhance the overall care experience for thoracic cancer patients during the peri-operative period.
Why it matters
Potential benefit: If successful, this trial could significantly improve recovery and quality of life for patients undergoing surgery for thoracic cancers.
How similar studies have gone: Other studies have shown promise in integrating complementary therapies into cancer care, but this approach is relatively novel in the context of thoracic surgery.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria • Adults eligible for complete resection of lung, gastric or esophageal cancer Exclusion criteria * Small cell, carcinoid, or gastrointestinal stromal (GIST) tumours * Any wedge resections of lung cancer * History of cancer with active treatment in the last 3 years (not including superficial bladder cancer or non-melanoma skin cancer) * Patients currently receiving care guided by an ND or who have previously seen an ND in the last 3 months * Pregnant or breastfeeding women\* * Any reason which, in the opinion of the Principal Investigator (or delegate), would prevent the subject from participating in the study * Use of an investigational drug or participation in an investigational study within 30 days prior to starting the study
Where it's running
-
The Ottawa Hospital
Ottawa, Ontario, Canada Recruiting -
Michael Garron Hospital
Toronto, Ontario, Canada Recruiting
Study contacts
- Principal investigator: Andrew Seely, MD, PhD, FRCSC — Ottawa Hospital Research Institute
- Study coordinator: Anna Fazekas, MA, CCRP
- Email: afazekas@toh.ca
- Phone: 613-737-8899
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CEA-targeted CAR-T for advanced CEA-positive solid tumors
This trial will try CEA-targeted CAR-T cell infusions in adults with advanced CEA-positive cancers (such as colorectal, gastric, esophageal, lung, or pancreatic cancer) to see if the treatment is safe and helps control the disease.
-
Virtual exercise program to preserve function and prevent disability during chemotherapy
This trial tests whether supervised resistance sessions by video plus short home aerobic workouts help adults 18–64 maintain strength and stay active while receiving curative-intent chemotherapy.
-
IDOV-Immune for advanced solid tumors
This trial will try a single IV infusion of an engineered oncolytic vaccinia virus called IDOV-Immune in adults with advanced solid tumors that no longer respond to standard treatments.
-
Evaluating BL-M07D1 for HER2 Expressing Solid Tumors
This study is testing a new treatment called BL-M07D1 to see if it is safe and effective for people with advanced solid tumors that have a specific protein called HER2 after they have tried other treatments.
-
Investigating HER3-DXd for advanced solid tumors
This study is testing a new drug called HER3-DXd to see if it can safely help people with advanced solid tumors like melanoma, head and neck cancer, and gastric cancer who have already tried other treatments.
-
Combination therapy using checkpoint inhibitors for advanced solid tumors
This study is testing a new combination treatment using special antibodies for people with advanced solid tumors like lung and liver cancer to see if it can be safer and more effective than current options.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.